First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten1,2, Michel W. J. M. Wouters1,3, Doranne L. Hilarius4, John B. Haanen5, Christian U. Blank6,5, Maureen J. B. Aarts7, Franchette W. P. J. van den Berkmortel8, Jan-Willem B. de Groot9, Geke A. P. Hospers10, Ellen Kapiteijn11, Djura Piersma12, Roos S. van Rijn13, Karijn P. M. Suijkerbuijk14, Willeke A. M. Blokx15, Bert-Jan J. ten Tije16, Astrid A. M. van der Veldt17, Art Vreugdenhil18, Marye J. Boers-Sonderen19 and Alfonsus J. M. van den Eertwegh2

BACKGROUND: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAFV600-mutant melanoma patients.

METHODS: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAFV600-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method.

RESULTS: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3–NE) vs. 19.8 months (95% CI: 16.7–24.3) and 65.4% (95% CI: 58.1–73.6) vs. 41.7% (95% CI: 34.2–51.0).

CONCLUSIONS: Our data suggest that in the matched BRAFV600-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.

As BRAF/MEK inhibitors have a rapid onset and a high overall response rate (ORR), they are often considered the preferred primary treatment for patients with extensive (symptomatic) disease and a BRAFV600-mutation. However, in such patients, the response duration is relatively short due to acquired resistance. As time to response for immunotherapy is generally longer and ORR lower, checkpoint inhibition is usually not the preferred treatment for BRAF-mutant patients with poor prognostic factors such as a poor performance score or elevated LDH. Therefore, the perception that checkpoint inhibition leads to more durable responses could at least partially be explained by the fact that patients with better

BACKGROUND: Over the last decade, new systemic treatment options have emerged in the treatment of metastatic melanoma. These approved treatments can be divided into two main groups: targeted therapy consisting of BRAF and MEK inhibitors1,2 and immunotherapy, anti-PD-1 and anti-CTLA-4 monoclonal antibodies.3-5 Their introduction has increased the overall survival of these patients.2-6 Based on clinical consensus, treatment choice depends on several prognostic and predictive factors such as BRAF-mutation status, lactate dehydrogenase levels (LDH), performance status or elevated LDH.8 Therefore, the perception that checkpoint inhibition leads to more durable responses could at least partially be explained by the fact that patients with better

1Dutch Institute for Clinical Auditing, Rijnburgerweg 10, Leiden 2333AA, The Netherlands; 2Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, Amsterdam 1081HZ, The Netherlands; 3Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands; 4Department of Pharmacy, Rode Kruis Ziekenhuis, Vondellaan 13, Beverwijk 1942LE, The Netherlands; 5Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands; 6Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands; 7Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, Maastricht 6225HX, The Netherlands; 8Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hofplein 1, Sittard-Geleen 6162BG, The Netherlands; 9Isala Oncology Center, Isala, Dokter van Heesweg 2, Zwolle 8025AB, The Netherlands; 10Department of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, Groningen 9713GZ, The Netherlands; 11Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, Leiden 2333AZ, The Netherlands; 12Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede 7512ZG, The Netherlands; 13Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, Leeuwarden 8934AD, The Netherlands; 14Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584CX, The Netherlands; 15Department of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands; 16Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda 4818CK, The Netherlands; 17Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, ‘s-Gravenhijkwal 230, Rotterdam 3015SC, The Netherlands; 18Department of Internal Medicine, Maxima Medical Centre, De Run 4600, Eindhoven 5504DB, The Netherlands and 19Department of Medical Oncology, Radboud University Medical Centre, Geer Grooteplein Zuid 10, Nijmegen 6525GA, The Netherlands Correspondence: Alfonsus J. M. van den Eertwegh (vandeneertwegh@amsterdamumc.nl)

Received: 2 July 2020 Revised: 30 November 2020 Accepted: 10 December 2020 Published online: 26 January 2021
prognostic factors are being treated with immunotherapy. Although interstudy comparison suggests that immunotherapy results in more durable responses as compared to targeted therapy, these results need to be interpreted with caution due to the potential biases associated with this type of analysis.

Due to the confounding by indication bias, a head-to-head comparison between both groups, based on real-world data is difficult. Propensity score matching, a statistical method developed by Rosenbaum and Rubin, accounts for the unequal distribution of confounders. A propensity score is the chance of receiving the treatment, based on measured confounders such as age and tumour stage. This method matches patients based on their propensity score, creating two groups with similar distribution of confounders.

In this study, we (1) compare OS of BRAF/MEK inhibitors and anti-PD-1 monotherapy in BRAF-mutant advanced melanoma patients, and (2) use propensity score matching to determine the overall survival in the BRAF/MEK inhibitors vs. anti-PD-1 mono-therapy groups after matching.

METHODS

Study design and population

This longitudinal observational study used data from the Dutch Melanoma Treatment Registry (DMTR), a population-based, prospective registry capturing all patients with unresectable stage IIIC and IV melanoma in the Netherlands. Since the 1 July 2013, all patients with unresectable stage IIIC or stage IV melanoma seen in one of the 14 melanoma centres have been registered in the DMTR. Data are prospectively registered from diagnosis until death. Patients are followed every three months for changes in disease status, patients’ characteristics or treatment characteristics by an independent trained data manager. A detailed description of the DMTR setup has been published by Jochems et al.

All patients of 18 years and older, diagnosed between 2014 and 2017 (dataset cut-off date was 01-08-2019) with unresectable stage IIIC and IV melanoma, with a known BRAFV600E-mutation who used anti-PD-1 monotherapy (pembrolizumab or nivolumab) or BRAF/MEK inhibitors (dabrafenib + trametinib or vemurafenib + cobimetinib) as a first-line systemic therapy, were selected for analysis. Combination therapies of encorafenib + binimetinib and ipilimumab + nivolumab were not yet available during this time period. Line of therapy was defined as the start of a new drug class. Patients with uveal or mucosal melanoma were excluded from this analysis.

Statistical analysis

Baseline patient- and disease characteristics of BRAFV600E-mutant patients were analysed using descriptive statistics. Categorical variables were compared using the Chi-square test. Overall survival (OS) was defined as time from start systemic treatment until death from any cause with corresponding two-sided 95% confidence intervals and was estimated using the Kaplan–Meier method. TTNT was defined as the time until next treatment of a new drug class or death from any cause. OS and TTNT between subgroups was compared using log-rank tests for categorical variables. Patients alive or lost to follow-up were right-censored at the time of last registered contact.

In order to reduce confounding by indication, propensity score matching was used. As a first step, a multivariable logistic regression analysis was used to estimate propensity scores. Covariates used for the multivariable logistic regression were age at diagnosis (<75, ≥75), baseline ECOG-performance status (0–1 and ≥2), baseline lactate dehydrogenase (LDH) (normal, 250–500 U/L and >500 U/L), stage at diagnosis (unresectable IIc, IV-M1a, M1b and IV-M1c), distant metastasis (<3 organ sites and ≥3 organ sites involved), brain metastases (none, asymptomatic, and symptomatic) and liver metastases (yes/no) and use of immunomodulating agents (corticosteroids, azathioprine and interferon). Covariates were chosen based on clinical practice and previous research identifying these prognostic risk factors. A Monte Carlo simulation study has demonstrated that his method of selecting covariates for propensity score matching works very well.

A multivariable Cox proportional hazards model was used to assess the association of prognostic factors with OS. Prognostic factors estimated were age at diagnosis (<75, ≥75), baseline ECOG-performance status (0–1 and ≥2), baseline lactate dehydrogenase (LDH; normal, 250–500 U/L and >500 U/L), distant metastases (<3 organ sites and ≥3 organ sites involved), brain metastases (none, asymptomatic and symptomatic) and liver metastases (yes/no). The proportional hazards assumption was tested with the scaled Schoenfeld residuals. None of the covariates violated the proportional hazards assumption.

For matching purposes, 1:1 nearest neighbour matching with a calliper set of 0.001 was used for propensity score matching. To assess the quality of matching, standardised mean differences for all covariates were calculated. Standardised mean differences of <0.1 were assumed to be negligible. After matching, a univariable Cox proportional hazards model with a robust variance estimator to account for the matched nature of the sample was used to estimate the relative change in hazard of survival. To address potential biases due to incomplete matching, we compared our results to a second matched sample set using optimal matching. Optimal matching forms matched pairs to minimise the average within-pair difference in propensity scores. We used both matching techniques in order to observe the influence of well-balanced prognostic factors across both groups in the nearest neighbour-matched group on OS and TTNT compared to the optimal matching method. Due to the matched nature, the use of a log-rank test comparing the survival curves will likely result in type I error rates that are artificially low, stratified log-rank tests were used to compare the survival curves of the matched samples. Statistical software used was R (version 3.5.2; packages car, tidyverse, survival and matchit).

RESULTS

Patient characteristics
Between 1-1-2014 and 31-12-2017, a total of 330 and 254 BRAF-mutant patients with unresectable stage IIIC or IV melanoma received BRAF/MEK inhibitors or anti-PD-1 monotherapy, respectively, as first-line systemic therapy (Fig. 1). Overall, patients receiving BRAF/MEK inhibitors as a first-line systemic treatment had a higher ECOG-performance status (≥2: 23.0% vs. 8.7%), elevated LDH levels, (50.3% vs 22.4%), IV-M1c disease (87.6% vs. 67.3%), brain metastases (41.8% vs. 18.5%), liver metastases (33.9% vs. 21.3%) and metastases in more organ sites (≥3 organ sites: 59.4% vs. 42.5%) (Table 1). There was no significant difference in age and gender between patients receiving first-line treatment with BRAF/MEK inhibitors and anti-PD-1 ligands. Median follow-up time, calculated with a reverse Kaplan–Meier method, was 28.3 months for the total population. Subsequent therapies are shown in Supplement 1 and subsequent therapies of progressive patients are shown in Supplement 2. Overall, progressive patients that received first-line BRAF/MEK inhibitors receive less second and third-line therapy compared to patients receiving first-line anti-PD-1, 61.3% vs. 94.2% and 6.5% vs.43.4%.

Predictors of receiving first-line BRAF/MEK inhibitors
To determine which factors were associated with receiving first-line BRAF/MEK inhibitors, a multivariable logistic regression was performed (Table 2). The results show that an ECOG-performance status of ≥2 (OR: 1.93, 95% CI: 1.11–3.44), elevated LDH (OR: 2.84, 95% CI: 1.86–4.38) and symptomatic brain metastases (OR: 3.84,
95% CI: 2.56–7.12) were all associated with higher odds of receiving first-line BRAF/MEK inhibitors. With unresectable stage IIIc as a reference, substage IV-M1b had lower odds of receiving first-line BRAF/MEK inhibitors (OR: 0.29, 95% CI: 0.11–0.74). Age ≥75 years, female gender, ≥3 organ sites, asymptomatic brain metastases and liver metastases were not significantly associated with receiving first-line BRAF/MEK inhibitors (p > 0.05).

Predictors of OS
In the multivariable Cox-regression on OS analysis age of ≥75 years (HR: 1.53, 95% CI: 1.10–2.13), ECOG-performance status ≥2 (HR: 2.30, 95% CI: 1.76–3.01), LDH > 500 U/L (HR: 3.38, 95% CI: 2.34–4.89) and symptomatic brain metastases (HR: 1.87, 95% CI: 1.44–2.43) were associated with a higher hazard of death. Female gender, asymptomatic brain metastases, liver metastases and ≥3 organ sites were not associated with a higher hazard of death (Table 3).

Propensity score matching
After 1:1 nearest neighbour propensity score matching, 310 patients were included in the final analysis: 155 patients who received first-line BRAF/MEK inhibitors (50%) and 155 patients who received first-line anti-PD-1 (50%). Groups did not differ with regards to age (median age: 62 vs. 62 years), gender (47.7% vs 47.7%), ECOG-performance status ≥2 (7.1% vs. 7.1), elevated LDH > 250 U/L (30.3% vs. 30.3%), stage IV-M1c (77.4% vs. 77.4%), organ sites ≥3 (45.8% vs. 45.2%), brain metastases (22.6% vs. 22.6%), liver metastases (21.9% vs 21.9%) and immunomodulating agents (13.5% vs. 13.5%). These results confirm satisfactory propensity score matching.

In total, 274 patients were not matched: 175 patients who received first-line BRAF-MEK and 99 patients receiving anti-PD-1 as a first-line treatment (Supplement 3). Overall, nonmatched patients who received BRAF/MEK inhibitors as first-line systemic

Fig. 1 Flow chart. Flow chart of the study population.
therapy had poorer ECOG-performance status (ECOG-performance status ≥2 37.1% vs. 11.1%) and more often had elevated LDH levels (68.0% vs. 10.1%), stage IV-M1c (96.6% vs. 51.5%) more ≥3 organ sites affected (73.1% vs. 37.4%), brain metastases (58.8% vs. 12.1%), liver metastases (44.6% vs. 20.2%) and used immunomodulating agents (38.3% vs. 9.1%) compared to the unmatched patients who received anti-PD-1 monotherapy.

Clinical outcomes
In the cohort before matching, patients treated with BRAF/MEK inhibitors as first-line systemic treatment were more likely to die compared to patients treated with anti-PD-1 monotherapy (p < 0.001, log-rank test). Kaplan–Meier estimates are shown in Fig. 2. Median overall survival was 11.0 months (95% CI: 9.9–13.7) in patients receiving first-line BRAF/MEK inhibitors vs. 42.3 months (95% CI: 34.8–NE) in patients receiving anti-PD-1 ligands as first-line therapy. Median TTNT was 7.0 months (95% CI: 6.2–8.7) in patients receiving first-line BRAF/MEK inhibitors vs. 18.9 months (95% CI: 11.0–24.4) in patients receiving anti-PD-1 ligands as first-line therapy. Six and twelve-month OS were also lower for first-line BRAF/MEK inhibitors compared to anti-PD-1 monotherapy, 75.9% (95% CI: 69.7–80.7) and 47.7% (95% CI: 38.1–57.2) vs. 91.3% (95% CI: 87.9–94.8) and 81.7% (95% CI: 77.0–86.6) (Table 4).

Nearest neighbour propensity matching. In the nearest neighbour-matched cohort (N = 310), the overall survival of first-line BRAF/MEK inhibitors was significantly lower compared to anti-PD-1 (stratified log-rank p < 0.001). This matched cohort only included patients treated with anti-PD-1 and BRAF/MEK inhibitors in which the propensity score of both patients was within the pre-set calliper. Median OS of first-line BRAF/MEK inhibitors was lower compared to the anti-PD-1 cohort, 19.8 months (95% CI: 16.7–24.3) vs. 42.3 (95% CI 37.3–NE). Median TTNT of first-line BRAF/MEK inhibitors was lower compared to anti-PD-1, 19.8 months (95% CI: 16.7–24.3) vs. 42.3 (95% CI 37.3–NE). Median TTNT of first-line BRAF/MEK inhibitors was lower compared to anti-PD-1, 19.8 months (95% CI: 16.7–24.3) vs. 42.3 (95% CI 37.3–NE).

Table 1. Baseline characteristics.

| Baseline variable                  | Original sample | Anti-PD-1 | p value | Nearest neighbour-matched sample | Anti-PD-1 | SMD |
|------------------------------------|----------------|----------|---------|----------------------------------|----------|-----|
| Age, median (range)                | (N = 330)      | (N = 254) | 0.177   | (N = 155)                        | (N = 155) | 0.027 |
| Gender                             |                |          |         |                                  |          |     |
| Male                               | 178 (53.9)     | 145 (57.1)| 0.500   | 81 (52.3)                        | 81 (52.3) | <0.001 |
| Female                             | 152 (46.1)     | 109 (42.9) |         | 74 (47.7)                        | 74 (47.7) |     |
| ECOG-performance status            |                |          |         |                                  |          |     |
| 0–1                                | 254 (77.0)     | 232 (91.3)| <0.001  | 144 (92.9)                       | 144 (92.9)| <0.001 |
| ≥2                                 | 76 (23.0)      | 22 (8.7)  |         | 11 (7.1)                         | 11 (7.1)  |     |
| LDH                                |                |          |         |                                  |          |     |
| Not determined/normal              | 164 (49.7)     | 197 (77.6)| <0.001  | 108 (69.7)                       | 108 (69.7)| <0.001 |
| 250–500 U/L                        | 108 (32.7)     | 55 (21.7) |         | 45 (29.0)                        | 45 (29.0) |     |
| >500 U/L                           | 58 (17.6)      | 2 (0.8)   |         | 2 (1.3)                          | 2 (1.3)   |     |
| Stage (7th edition AJCC)           |                |          |         |                                  |          |     |
| Unresectable IIIc                  | 15 (4.5)       | 14 (5.5)  | <0.001  | 10 (6.5)                         | 10 (6.5)  | <0.001 |
| IV-M1a                             | 13 (3.9)       | 29 (11.4) |         | 13 (8.4)                         | 13 (8.4)  |     |
| IV-M1b                             | 13 (3.9)       | 40 (15.7) |         | 12 (7.7)                         | 12 (7.7)  |     |
| IV-M1c                             | 289 (87.6)     | 171 (67.3)|         | 120 (77.4)                       | 120 (77.4)|     |
| Brain metastases                   |                |          |         |                                  |          |     |
| No                                 | 192 (58.2)     | 207 (81.5)| <0.001  | 120 (77.4)                       | 120 (77.4)| <0.001 |
| Yes, asymptomatic                  | 42 (12.7)      | 24 (9.4)  |         | 15 (9.7)                         | 15 (9.7)  |     |
| Yes, symptomatic                   | 96 (29.1)      | 23 (9.1)  | <0.001  | 20 (12.9)                        | 20 (12.9) |     |
| Liver metastases                   |                |          |         |                                  |          |     |
| No                                 | 218 (66.1)     | 200 (78.7)|         | 121 (78.1)                       | 121 (78.1)| <0.001 |
| Yes                                | 112 (33.9)     | 54 (21.3) |         | 34 (21.9)                        | 34 (21.9) |     |
| Organ sites                        |                |          |         |                                  |          |     |
| 0–2                                | 134 (40.6)     | 146 (57.5)| 0.001   | 86 (55.5)                        | 83 (53.5) | <0.001 |
| ≥3                                 | 196 (59.4)     | 108 (42.5)|         | 69 (44.5)                        | 72 (46.5) |     |
| Immunomodulating agents            |                |          |         |                                  |          |     |
| No                                 | 242 (73.3)     | 224 (88.2)| <0.001  | 134 (86.5)                       | 134 (86.5)| <0.001 |
| Yes                                | 88 (26.7)      | 30 (11.8) |         | 21 (13.5)                        | 21 (13.5) |     |
| BRAFV600E mutation                 |                |          |         |                                  |          |     |
| V600E                              | 274 (83.0)     | 212 (83.5)| 0.833   | 130 (83.9)                       | 132 (85.2)| 0.073 |
| V600K                              | 44 (13.3)      | 35 (13.8) |         | 19 (12.3)                        | 19 (12.3) |     |
| V600R/D/E2                         | 12 (3.6)       | 7 (2.8)   |         | 6 (3.9)                          | 4 (2.6)   |     |

Comparison of baseline characteristics of patients receiving BRAF/MEK inhibitors or anti-PD-1 as a first-line treatment in the original sample and the matched sample.
inhibitors was not significantly lower compared to the anti-PD-1 cohort, 10.1 months (95% CI: 7.7–15.0) vs. 14.6 (95% CI: 10.1–27.7). Six-, 12- and 24-month OS was also lower for BRAF/MEK inhibitors compared to anti-PD-1 monotherapy, 92.9% (95% CI: 89.9–97.0), 83.0% (95% CI: 77.3–89.2) and 65.4% (58.1–73.6) vs. 84.3% (95% CI: 78.7–90.3), 65.3% (95% CI: 58.2–73.3) and 41.7% (95% CI: 34.2–51.0) (Table 4). Kaplan–Meier estimates of the nearest neighbour-matched cohort are shown in Fig. 3. The estimated HR with a robust variance estimator was 0.50 (95% CI: 0.36–0.70) Thus, treatment with first-line anti-PD-1 ligands reduced the hazard of death by 50% in this matched sample. Overall survival of the nonmatched patients receiving BRAF/MEK inhibitors was significantly lower compared to anti-PD-1 (log-rank p<0.001) (Supplement 4).

**Optimal matching.** In the optimal matched cohort (N=508), overall survival was significantly lower for BRAF/MEK inhibitors compared to anti-PD-1 monotherapy (stratified log-rank p<0.001). This matched cohort included all patients treated with first-line anti-PD-1 matched with the most alike set of patients treated with first-line BRAF/MEK inhibitors. Median OS of first-line BRAF/MEK inhibitors was lower compared to anti-PD-1 monotherapy, 15.6 months (95% CI: 12.4–19.1), vs. 42.3 months (95% CI: 34.4–NE). Median TTTN of first-line BRAF/MEK inhibitors was lower compared to anti-PD-1 monotherapy, 7.6 months (95% CI: 6.1–9.9), vs. 18.9 months (95% CI: 11.0–24.4). Six-, 12- and 24-month OS was also lower for BRAF/MEK inhibitors compared to anti-PD-1 monotherapy, 83.7% (95% CI: 79.3–88.4), 57.1% (95% CI: 51.3–63.6) and 34.4 (95% CI: 28.7–41.3) vs. 91.3% (95% CI: 87.9–94.8), 81.7% (95% CI: 77.0–86.6) and 64.0 (95% CI: 58.2–70.4) (Table 4). Kaplan–Meier estimates of the optimal matched cohort are shown in Fig. 4. The estimated HR with a robust variance estimator was 0.43 (95% CI: 0.34–0.56). Thus, treatment with first-line anti-PD-1 reduced the hazard of death by 57% in the optimal matched sample.

**DISCUSSION**

This report, based on real-world population-based data, describes the overall survival of BRAF*V600E*-mutant advanced melanoma patients after using first-line treatment with BRAF/MEK inhibitors or anti-PD-1 monotherapy. In total 310 patients were matched, resulting in 155 matched pairs. In the matched cohort, patients treated with anti-PD-1 monotherapy as a first-line treatment showed a higher 2-year survival compared to patients treated with first-line BRAF-MEK. Median OS in the anti-PD-1 monotherapy cohort was 42.3 months while the median OS was 19.8 months in patients receiving BRAF-MEK inhibitors as first-line treatment.

In the nearest neighbour-matched cohort, patients treated with anti-PD-1 as a first-line treatment have higher OS compared to patients treated with BRAF/MEK inhibitors as a first-line treatment. There were also patients who could not be matched. Overall, we matched patients with relatively good prognosis factors who

---

**Table 2. Multivariable logistic regression.**

| Variables                      | OR   | 95% CI        | p value |
|--------------------------------|------|---------------|---------|
| (Intercept)                    | 0.84 | (0.40–1.82)   | 0.659   |
| Age (categories)               |      |               |         |
| <75 years                      | Ref  |               |         |
| ≥75 years                      | 1.54 | (0.86–2.78)   | 0.149   |
| Gender                         |      |               |         |
| Male                           | Ref  |               |         |
| Female                         | 1.34 | (0.92–1.95)   | 0.132   |
| ECOG-performance status        |      |               |         |
| 0–1                            | Ref  |               |         |
| ≥2                             | 1.59 | (0.89–2.89)   | 0.123   |
| LDH                            |      |               |         |
| Not determined/normal          | Ref  |               |         |
| 250–500 U/L                    | 2.03 | (1.86–4.38)   | 0.002   |
| >500 U/L                       | 30.73| (8.77–195.30)| <0.001  |
| Stage (7th edition AJCC)       |      |               |         |
| Unresectable IIIc              | Ref  |               |         |
| IV-M1a                         | 0.47 | (0.17–1.27)   | 0.140   |
| IV-M1b                         | 0.33 | (0.12–0.88)   | 0.029   |
| IV-M1c                         | 0.58 | (0.25–1.34)   | 0.201   |
| Organ sites                    |      |               |         |
| 0–2                            | Ref  |               |         |
| ≥3                             | 1.52 | (0.98–2.35)   | 0.063   |
| Brain metastases               |      |               |         |
| No                             | Ref  |               |         |
| Yes, asymptomatic              | 1.40 | (0.76–2.60)   | 0.279   |
| Yes, symptomatic               | 3.97 | (2.22–7.35)   | <0.001  |
| Liver metastases               |      |               |         |
| No                             | Ref  |               |         |
| Yes                            | 0.89 | (0.54–1.45)   | 0.629   |
| Immunomodulating agents        |      |               |         |
| No                             | Ref  |               |         |
| Yes                            | 1.41 | (0.81–2.47)   | 0.222   |

Multivariable logistic regression of receiving first-line BRAF-MEK inhibitor treatment. 

**LDH** lactate dehydrogenase, OR odds ratio, CI confidence interval.

**Table 3. Multivariable Cox-regression analysis of OS.**

| Variables                      | N   | HR   | 95% CI        | p value |
|--------------------------------|-----|------|---------------|---------|
| Age                            |     |      |               |         |
| <75 years                      | 520 | 1    |               |         |
| ≥75 years                      | 64  | 1.53 | (1.10–2.13)   | 0.012   |
| Gender                         |     |      |               |         |
| Female                         | 323 | 1    |               |         |
| Male                           | 261 | 0.94 | (0.75–1.17)   | 0.585   |
| ECOG-performance status        |     |      |               |         |
| 0–1                            | 486 | 1    |               |         |
| ≥2                             | 98  | 2.30 | (1.76–3.01)   | <0.001  |
| LDH                            |     |      |               |         |
| Normal                         | 361 | 1    |               |         |
| 250–500 U/L                    | 163 | 1.28 | (0.99–1.65)   | 0.065   |
| >500 U/L                       | 60  | 3.38 | (2.34–4.89)   | <0.001  |
| Brain metastases               |     |      |               |         |
| No                             | 418 | 1    |               |         |
| Yes                            | 166 | 1.18 | (0.9–1.55)    | 0.241   |
| Number of organ sites          |     |      |               |         |
| 0–2                            | 289 | 1    |               |         |
| ≥3                             | 295 | 1.25 | (0.96–1.62)   | 0.096   |

**LDH** lactate dehydrogenase, HR hazard ratio, CI confidence interval.
received BRAF/MEK inhibitors with patients with relatively poor prognosis factors who received anti-PD-1 monotherapy as first-line systemic therapy. The unmatched patients consisted of patients with poor prognostic factors who received BRAF/MEK inhibitors as first-line therapy and the patients with good prognostic factors who received anti-PD-1 as first-line systemic therapy. In the optimal matching method, we matched all patients receiving first-line anti-PD-1, resulting in lower OS for BRAF/MEK inhibitors as sicker patients were matched, which could, in turn, lead to residual confounding. Consequently, we cannot compare the efficacy of BRAF/MEK inhibitors or anti-PD-1 in the unmatched group. In BRAF-mutant patients with a very poor prognosis, BRAF-MEK inhibitors might be the preferred choice of first-line treatment as this treatment results in quick antitumour response.

This study suggests that in the matched cohort, consisting of patients with relative favourable patient and tumour characteristics, anti-PD-1 monotherapy is the first-line treatment option of choice. However, the results need to be confirmed in randomised clinical trials to assess optimal front-line-and sequence therapy. Currently, several clinical trials are investigating the optimal front-line treatment of immunotherapy and targeted therapy. The COWBOY study evaluates a planned sequence vemurafenib and cobimetinib, followed by ipilimumab and nivolumab vs. ipilimumab and nivolumab or the opposite sequence or encorafenib plus binimetinib and trametinib. The SECOMBIT (NCT02968303) evaluates a sequence of dabrafenib and trametinib until progression, followed by ipilimumab and nivolumab or the opposite sequence or encorafenib plus binimetinib for 8 weeks followed by ipilimumab plus nivolumab until progression followed by encorafenib plus binimetinib. These studies are expected to be completed by the end of 2021 and 2022.
In Phase 3 RCTs, 1-year survival was 74.1% for pembrolizumab and 72.9% for nivolumab. Comparing the results of this study with the randomised clinical trials of both anti-PD-1 ligands, we find a higher 1-year survival (81.7%, 95% CI 77.0–86.6). This is remarkable because we would expect 1-year survival of patients treated in clinical practice to be similar or worse due to unfavourable patient and tumour characteristics. However, in the CHECKMATE-066 study, only BRAF wild-type patients were included and the KEYNOTE-006 included only 35% of BRAF-mutant patients. These patients lack treatment options with BRAF/MEK inhibitors.

Fig. 3  Kaplan–Meier estimate OS and TTNT of the nearest neighbour-matched sample. Kaplan–Meier estimates of OS (left) and TTNT (right) for the nearest neighbour-matched cohort. Confidence interval is displayed by the shadow of both curves.

Fig. 4  Kaplan–Meier estimate of the optimal matched sample. Kaplan–Meier estimates of OS (left) and TTNT (right) for the optimal matched cohort. Confidence interval is displayed by the shadow of both curves.
which may result in fewer treatment options available after progression on anti-PD-1 treatment. On the other hand, in our matched anti-PD-1 cohort, 7.1% of patients had a baseline ECOG-performance status of ≥2. These patients have been excluded from the previously mentioned RCT’s and as a result, we would expect that the clinical outcomes of this study would be worse compared to RCT’s. Compared to Phase 3 RCT’s of BRAF/MEK inhibitors, one year survival was 71.2% for dabrafenib and trametinib and 74.5% for vemurafenib and cobimetinib.\textsuperscript{2,20} Compared to the 1-year survival of this study, we find a lower 1-year survival of 65.3% (95% CI: 58.2–73.3). Differences in survival could be related to a higher age (62 vs. 55), inclusion of ECOG ≥2 (7.1%), more patients with IV-M1c disease (77% vs. 62–63%) and inclusion of patients with brain metastases (22.6%) in our matched sample.

Another real-world study investigating the outcomes of first-line immunotherapy and targeted therapy was performed by Luke et al.\textsuperscript{27} Opposed to our current study, they find a lack of survival benefit for patients receiving first-line immunotherapy, despite a favourable imbalance of prognostic factors. These differences could be explained by the percentage of M1c patients (77.4%) in our study vs. 59.7% and 51.6% in the study by Luke et al. A direct comparison between both studies is hard due to differences in patient and tumour characteristics, study design and geographic location.

There are limitations to this study. First, this study did not include patients who received ipilimumab monotherapy or ipilimumab combined with nivolumab. Ipilimumab monotherapy is no longer given as first-line treatment since anti-PD-1 has proven superior efficacy.\textsuperscript{28} However, combination therapy of ipilimumab and nivolumab has proven to be effective in metastatic melanoma patients in the CHECKMATE-067 trial.\textsuperscript{29} We did not have enough patients who received combination therapy of ipilimumab and nivolumab to make a reliable analysis of this group. Second, the observational nature of the DMTR may have introduced bias. However, since the start of this registry, independent data managers have been trained annually and data are checked and confirmed by treating physicians. The online registration platform warns data managers of inconsistent or missing values in the registry. Previous studies have shown the quality and validity of the Dutch population-based registries.\textsuperscript{18} We therefore argue that the data used in this study is of high quality. The third limitation is that we could not assess how subsequent therapies impact the outcome. By studying patients receiving second-line treatment, we would introduce a selection bias. Only patients fit enough would be able to receive second-line treatment. Studying the impact of subsequent therapies on outcomes would require a randomised controlled trial with several predefined arms. In the real-world, choice of type of subsequent therapy depends on patient and tumour characteristics as well as preference of the oncologist.

Based on the matched cohort, our data suggest that in BRAF\textsuperscript{V600D}-mutant cutaneous metastatic melanoma patients, anti-PD-1 monotherapy should be the preferred treatment if a quick antitumour response, for example for symptom relief, is not the primary aim of treatment. Additional results from RCTs are necessary to confirm these results to determine optimal front-line and sequential therapy for BRAF-mutant cutaneous metastatic melanoma patients.

Acknowledgements
We thank all physicians and data managers who registered the patient data in the Dutch Melanoma Treatment Registry.

Author Contributions
J.B. performed the analyses and wrote the manuscript. M.W. was responsible for the study conception and design, analysis and interpretation of data and drafting of the manuscript. W.B. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. J.H. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. C.B. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. M.A. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. F.B. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. K.S. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. G.H. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. E.K. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. D.P. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. R.R. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. K.S. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. A.V. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. G.V. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. M.B. performed data acquisition, study conception, helped with the analysis and interpretation of the data, drafted the manuscript and performed critical revision and final approval of the manuscript. A.E. was responsible for the study conception and design, analysis and interpretation of data and drafting of the manuscript.

Additional Information
Ethics approval and consent to participate In compliance with Dutch regulations, the DMTR was approved by a medical ethical committee (METC Leiden University Medical Center, 2013) and is not considered subject to the Medical Research Involving Human Subjects Act.

Data availability The datasets generated during and/or analysed during the current study are not publicly available due to privacy regulations in the Netherlands but are available from the corresponding author on reasonable request.

Competing interests A.J.M.V.D.E. has consulting/advisory relationships with BMS, Roche, MSD, and Novartis. He received a study grant from Roche. J.W.D.G. has received personal fees outside the submitted work from Bristol-Myers Squibb, Pierre Fabre, Servier, MSD, Novartis. GH consultancy/advisory relationships with Amgen, Bristol-Myers Squibb, Roche, MSD, Pﬁzer, Novartis and has received research grants not related to this paper from Bristol-Myers Squibb, Seereave. E.K. has consultancy/advisory relationships with Amgen, Bristol-Myers Squibb, Novartis, Merck, Pierre Fabre, and received research grants not related to this paper from Bristol-Myers Squibb. K.P.M.S. has consulting/advisory relationships with BMS and MSD. She received honoraria from Novartis, Pierre Fabre, and Roche. A.V.D.V. has consultancy relationships with Bristol-Myers Squibb, MSD, Roche, Novartis, Pierre Fabre, Pﬁzer, Sanofi, Ipsen, Eisai. J.H. has advisory relationships with Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celsius Therapeutics, GSK, Immunocore, Ipsen, MSD, Merck Serono, Novartis, Neon Therapeutics, Pﬁzer, Roche/Genentech, Sanofi, Seattle Genetics and has received research grants not related to this paper from Novartis, Bristol-Myers Squibb, MSD, Neon Therapeutics. C.U.B. has received commercial research grants from Novartis, Bristol-Myers Squibb, and NanoString; is a paid advisor to the Board of Directors for Bristol-Myers Squibb, MSD, Roche, NanoString, and ImmuKnow. C.B. has consultancy relationships with Pierre Fabre, MSD and Novartis. All grants were paid to the institutions. The funders had no role in the writing of this article or decision to submit it for publication. All remaining authors have declared no conﬂicts of interest.
Funding information
For the Dutch Melanoma Treatment Registry (DMTR), the Dutch Institute for Clinical Auditing foundation received a start-up grant from governmental organisation The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis and Roche Pharma. Roche Pharma stopped funding in 2019 and Pierre Fabre started funding of the DMTR in 2019. For this work no funding was granted.

Supplementary information is available for this paper at https://doi.org/10.1038/s41416-020-01229-1.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
2. Robert, C., Karasiewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stoilakovski, D. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30–39 (2015).
3. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
4. Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J. J., Mortier, L. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390, 1853–1862, https://doi.org/10.1016/S0140-6736(17)31601-X (2017).
5. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D. et al. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N. Engl. J. Med. 373, 23–34 (2015).
6. NCCN clinical practice guidelines in oncology (NCCN guidelines): cutaneous melanoma. Nati Compr. Cancer Netw. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (2019).
7. Pelster, M. S. & Amanja, R. N. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther. Adv. Med. Oncol. 11, 1–19 (2019).
8. Schouwenburg, M. G., Suijkerbuijk, K. P. M., Koomstra, R. H. T., Jochems, A., Van Zeijl, M. C. T., Van Den Eertwegh, A. J. M. et al. Switching to immune checkpoint inhibitors upon response to targeted therapy: the road to long-term survival in advanced melanoma patients with highly elevated serum LDH? Cancers (Basel). 11 (2019).
9. Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J. J., Hauschild, A. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. Eur. J. Cancer 83, 247–257 (2017).
10. Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in observational studies for causal effects. Matched Samp. Causal Eff. 70, 170–184 (2006).
11. Klungel, O. H., Martinez, E. P., Psaty, B. M., Grobbee, D. E., Sullivan, S. D., Stricker, B. H. C. et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J. Clin. Epidemiol. 57, 1223–1231 (2004).
12. Evaluation, M. & Olmos, A. Propensity scores: a practical introduction using R. J. Multidiscip. Eval. 11, 68–88 (2015).
13. Jochems, A., Schouwenburg, M. G., Leenenman, B., Franken, M. G., van den Eertwegh, A. J. M., Haanen, J. B. A. G. et al. Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. Eur. J. Cancer 72, 156–165, http://www.ncbi.nlm.nih.gov/pubmed/28030784 (2017).
14. Manola, J., Atkins, M., Ibrahim, J. & Kirkwood, J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J. Clin. Oncol. 18, 3782–3793 (2000).
15. Long, G. V., Grob, J. J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D. et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 17, 1743–1754, https://doi.org/10.1016/S1470-2045(16)30578-2 (2016).
16. Austin, P. C., Grootendorst, P. & Anderson, G. M. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat. Med. 26, 734–753 (2007).
17. Lin, D. Y. & Wei, L. J. The Robust Inference for the Cox Proportional Hazards Model. J. Am. Stat. Assoc. 84, 1074 (1989).
18. Austin, P. C. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat. Med. 33, 1242–1258 (2014).
19. Austin, P. C. A comparison of 12 algorithms for matching on the propensity score. Stat. Med. 33, 1057–1069 (2014).
20. Austin, P. C. Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analyses. Int. J. Biostat. 5, 1–21 (2009).
21. Yushak, M., Chapman, P., Robert, C. & Kudchadkar, R. Systemic therapy options for patients with unresectable melanoma. Am. Soc. Clin. Oncol. Educ. B. 37, 661–672 (2017).
22. Rijksuniversiteit Groningen. Induction Therapy with Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (COBOY), Identifier: NCT02968363 https://clinicaltrials.gov/ct2/show/study/NCT02968363 (2017).
23. National Cancer Institute (NCI). DREAMseq (Double, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial, Identifier: NCT02224781. https://clinicaltrials.gov/ct2/show/NCT02224781.
24. Onlus Fondazione Melanoma. A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation. Identifier: NCT02. https://clinicaltrials.gov/ct2/show/NCT02631447 (2016).
25. Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
26. Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszky, G., Di Giacomo, A. M. et al. Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17, 1248–1260 (2016).
27. Luke, J. J., Ghate, S. R., Kish, J., Lee, C. H., McAllister, L., Mehta, S. et al. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. Future Oncol. 15, 2933–2942 (2019).
28. Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc analysis of outcomes: reporting measures of effect similar to those used in randomized experiments. Stat. Med. 33, 1242–1258 (2014).
29. van der Werf, L. R., Voeten, S. C., van Loë, C. M. M., Karthaus, E. G., Wouters, M. W. J. M., Prins, H. A. Data verification of nationwide clinical quality registries. BJU Open 3, 857–864 (2019).